Annals of Hematology

, Volume 93, Issue 6, pp 913–921 | Cite as

Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)

  • Marcus Hentrich
  • Christian Hoffmann
  • Franz Mosthaf
  • Markus Müller
  • Jan Siehl
  • Christoph Wyen
  • Manfred Hensel
Review Article


AIDS-related aggressive B cell lymphoma (HIV-NHL) is the second most common HIV-associated malignancy. In contrast, Hodgkin-lymphoma (HL) is one of the most common non-AIDS-defining malignancies. Current evidence-based recommendations for the treatment of HIV-associated lymphoma (HIV-lymphoma) are not available. A panel of experts in the field of HIV-related lymphoma performed literature searches of the PubMed, Medline, and Cochrane databases. The consensus process was carried out as an e-mail and meeting-based discussion group. Six cycles of R-CHOP or R-EPOCH are standard of care for patients (pts) with diffuse large B cell lymphoma (DLBCL). Pts with Burkitt lymphoma and good performance status should receive dose-intensive regimens such as the GMALL B-ALL/NHL protocol. Standard therapy has not been defined for pts with plasmablastic and primary effusion lymphoma. Pts with lymphoma in sensitive relapse should receive high-dose chemotherapy followed by autologous stem cell transplantation. Stage- and risk adapted treatment yields high remission and survival rates in pts with HIV-HL similar to those achieved in HIV-negative HL pts. Combination antiretroviral therapy (cART) should be applied concurrently to chemotherapy provided that pharmacokinetic interactions are being considered. Pts with HIV-lymphoma should usually be treated in an identical manner to HIV-negative patients.


HIV-associated lymphoma AIDS-related lymphoma HIV-associated Hodgkin lymphoma HIV-related Hodgkin lymphoma 


Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Lewden C, May T, Rosenthal E, Burty C, Bonnet F et al (2008) Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic). J AIDS 48:590–598Google Scholar
  2. 2.
    Kish MA (2001) Guide to development of practice guidelines. Clin Infect Dis 32:851–854CrossRefPubMedGoogle Scholar
  3. 3.
    Seaberg EC, Wiley D, Martínez-Maza O, Chmiel JS, Kingesley L et al (2010) Cancer incidence in the Multicenter AIDS Cohort Study before and during the HAART era: 1984–2007. Cancer 116:5507–5516PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS et al (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20:1645–1654CrossRefPubMedGoogle Scholar
  5. 5.
    Bower M, Fisher M, Hill T, Reeves I, Walsh J et al (2009) CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK. Haematologica 94:875–880PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E et al (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 10:1152–2259CrossRefPubMedGoogle Scholar
  7. 7.
    Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K et al (2010) Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 28:773–779PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C et al (2012) Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol 87:749–753CrossRefPubMedGoogle Scholar
  9. 9.
    Raphael M, Said J, Borisch B, Cesarman E, Harris NL et al (2008) Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon, pp 340–342Google Scholar
  10. 10.
    Chen YB, Rahemtullah A, Hochberg E (2007) Primary effusion lymphoma. Oncologist 12:569–576CrossRefPubMedGoogle Scholar
  11. 11.
    Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL (2008) Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 8:261–267CrossRefPubMedGoogle Scholar
  12. 12.
    Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O et al (2012) Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl7):vii78–82PubMedGoogle Scholar
  13. 13.
    Navarro WH, Kaplan LD (2006) AIDS-related lymphoproliferative disease. Blood 107:13–20CrossRefPubMedGoogle Scholar
  14. 14.
    Hoffmann C, Wolf E, Fätkenheuer G, Buhk T, Stoehr A et al (2003) Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 17:1521–1529CrossRefPubMedGoogle Scholar
  15. 15.
    Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C et al (2005) A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 143:265–273CrossRefPubMedGoogle Scholar
  16. 16.
    Weiss R, Mitrou P, Arastéh K, Schuermann D, Hentrich M et al (2006) Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival—results of the German Multicenter Trial. Cancer 106:1560–1568CrossRefPubMedGoogle Scholar
  17. 17.
    Schommers P, Wyen C, Hentrich M, Gillor D, Zoufaly A (2013) Poor outcome of HIV-infected patients with plasmablastic lymphoma (PBL)—results from the German AIDS related lymphoma (ARL) cohort study. AIDS 27:842–845CrossRefPubMedGoogle Scholar
  18. 18.
    Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S et al (2008) British HIV association guidelines for HIV-associated malignancies 2008. HIV Med 9:336–388CrossRefPubMedGoogle Scholar
  19. 19.
    European AIDS Clinical Society guidelines Version 7 October 2013 (2013). Part II: ART in HIV-positive persons.
  20. 20.
    Cingolani A, Torti L, Pinnetti C, de Gaetano DK, Murri R et al (2010) Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. AIDS 24:2408–2412PubMedGoogle Scholar
  21. 21.
    Ezzat HM, Cheung MC, Hicks LK, Boro J, Montaner JS et al (2012) Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leuk Lymphoma 53:2390–2396CrossRefPubMedGoogle Scholar
  22. 22.
    Bower M, Stebbing J, Tuthill M, Campbell V, Krell J et al (2008) Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood 111:3986–3990CrossRefPubMedGoogle Scholar
  23. 23.
    Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK et al (2012) Stage-adapted treatment of human immunodeficiency virus associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol 30:4117–4123CrossRefPubMedGoogle Scholar
  24. 24.
    Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF et al (2003) Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101:4653–4659CrossRefPubMedGoogle Scholar
  25. 25.
    Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilientfeld-Total M (2013) Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 92:433–442PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    European AIDS Clinical Society guidelines Version 7 October 2013 (2013). Part V: Opportunistic infections.
  27. 27.
    Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS et al (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199–3202CrossRefPubMedGoogle Scholar
  28. 28.
    Mandalà M, Fagiuoli S, Francisci D, Bruno R, Merelli B et al (2013) Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol 87:12–27CrossRefPubMedGoogle Scholar
  29. 29.
    Sandherr M, Einsele H, Hebart H, Kahl C, Kern W et al (2006) Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17:1051–1059CrossRefPubMedGoogle Scholar
  30. 30.
    Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ et al (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113–112PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E et al (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538–1543PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A et al (2006) Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol 24:4123–4128CrossRefPubMedGoogle Scholar
  33. 33.
    Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P et al (2008) Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 140:411–419CrossRefPubMedGoogle Scholar
  34. 34.
    Ratner L, Lee J, Tang S, Redden D, Hamzeh F et al (2001) Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19:2171–2178PubMedGoogle Scholar
  35. 35.
    Spina M, Jäger U, Sparano JA, Talamini R, Simonelli C et al (2005) Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 105:1891–1897CrossRefPubMedGoogle Scholar
  36. 36.
    Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS et al (2010) The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 115:3017–3024PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC et al (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 115:3008–3016PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M et al (2012) Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS 26:457–464CrossRefPubMedGoogle Scholar
  39. 39.
    Barta S, Xue X, Wang D, Tamari R, Lee JY et al (2013) Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood 122:3251–3262CrossRefPubMedGoogle Scholar
  40. 40.
    Levine AM, Noy A, Lee JY, Tam W, Ramos JC et al (2013) Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol 31:58–64PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A et al (2004) Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 22:1491–1500CrossRefPubMedGoogle Scholar
  42. 42.
    Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391CrossRefPubMedGoogle Scholar
  43. 43.
    Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E et al (2009) Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 27:5039–5048PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Spina M, Chimienti E, Martellotta F, Vaccher E, Berretta M et al (2010) Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 116:1495–1501CrossRefPubMedGoogle Scholar
  45. 45.
    Dunleavy D, Wilson WH (2012) How I treat HIV-associated lymphoma. Blood 119:3245–3255PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113:3896–3902CrossRefPubMedGoogle Scholar
  47. 47.
    Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E et al (2012) CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 23:1267–1273CrossRefPubMedGoogle Scholar
  48. 48.
    Kridel R, Dietrich PY (2011) Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncology 12:1258–1266CrossRefPubMedGoogle Scholar
  49. 49.
    Herbert K, Wolff M, Carney D, Westerman DA, Januszewicz H et al (2008) The addition of systemic high-dose methotrexate (HD-MTX) to intrathecal chemotherapy (IT) for central nervous system (CNS) prophylaxis substantilly reduces CNS recurrence rates in patients with at-risk aggressive lymphoma: a historically controlled prospective study. Blood 112(ASH Annual meeting abstracts):3596Google Scholar
  50. 50.
    Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C et al (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116:4283–4290CrossRefPubMedGoogle Scholar
  51. 51.
    Mazhar D, Stebbbing J, Lewis R, Nelson M, Gazzard BG, Bower M (2006) The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood 107:3412–3414CrossRefPubMedGoogle Scholar
  52. 52.
    Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, Van Lunzen J et al (2006) AIDS-associated Burkitt- or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 47:1872–1880CrossRefPubMedGoogle Scholar
  53. 53.
    Ribera J-M, Garcıa O, Grande C, Esteve J, Oriol A et al (2013) Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer 119:1660–1668CrossRefPubMedGoogle Scholar
  54. 54.
    Xicoy B, Ribera J-M, Müller M, García O, Hoffmann C et al. (2014) Dose-intense chemotherapy including rituximab is highly effective but toxic in HIV-infected patients with Burkitt's lymphoma/eukemia: parallel study of 81 patients. Leuk Lymphoma Feb 25 [Epub ahead of print]Google Scholar
  55. 55.
    Cortes J, Thomas D, Rios A, Koller C, O’Brien S et al (2002) Hyperfractionated cylclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94:1492–1499CrossRefPubMedGoogle Scholar
  56. 56.
    Wang ES, Strauss DJ, Teruya-Feldstein J, Qin J, Portlock C et al (2003) Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 98:1196–1205CrossRefPubMedGoogle Scholar
  57. 57.
    Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT et al (2007) Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 110:2846–2854CrossRefPubMedGoogle Scholar
  58. 58.
    Montoto S, Wilson J, Shaw K, Heath M, Wilson A et al (2010) Excellent immunological recovery following CODOXM/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma. AIDS 24:851–856CrossRefPubMedGoogle Scholar
  59. 59.
    Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D et al (2013) Low-intensity therapy in adults with Burkitt's lymphoma. New Engl J Med 369:1915–1925CrossRefPubMedGoogle Scholar
  60. 60.
    Castillo JJ, Furman M, Beltrán BE, Bibas M, Bower M et al (2012) Human immunodeficiency virus-associated plasmablastic lymphoma. Poor prognosis in the era of highly active antiretroviral therapy. Cancer 118:5270–5277CrossRefPubMedGoogle Scholar
  61. 61.
    Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H (2009) Response of AIDS related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol 27(suppl abstr):e19562Google Scholar
  62. 62.
    Saba NS, Dang D, Saba J, Cao C, Janbain M et al (2013) Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie 36:287–291CrossRefPubMedGoogle Scholar
  63. 63.
    Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R et al (2003) Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 21:3948–3954CrossRefPubMedGoogle Scholar
  64. 64.
    Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C et al (2005) Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 23:4372–4380CrossRefPubMedGoogle Scholar
  65. 65.
    Oksenhendler E, Boulanger E, Galicier L, Du MQ, Dupin N et al (2002) High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99:2331–2336CrossRefPubMedGoogle Scholar
  66. 66.
    Bower M, Powles T, Williams S, Davis TN, Atkins M et al (2007) Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 147:836–839CrossRefPubMedGoogle Scholar
  67. 67.
    Bower M (2010) How I treat HIV-associated multicentric Castleman disease. Blood 116:4415–4421CrossRefPubMedGoogle Scholar
  68. 68.
    Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M et al (2007) Prospective study of rituximab in chemotherapy- dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 Castleman Trial. J Clin Oncol 25:3350–3356CrossRefPubMedGoogle Scholar
  69. 69.
    Hoffmann C, Schmid H, Müller M, Teutsch C, van Lunzen J et al (2011) Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 118:3499–3503CrossRefPubMedGoogle Scholar
  70. 70.
    Gabarre J, Marcelin A-G, Azar N, Choquet S, Lévy V et al (2004) High-dose therapy plus autologous hematopietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV-disease. Haematologica 89:1100–1108PubMedGoogle Scholar
  71. 71.
    Re A, Michieli M, Casari S, Allione B, Cattaneo C et al (2009) High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 114:1306–1313CrossRefPubMedGoogle Scholar
  72. 72.
    Balsalobre P, Diez-Martin JL, Re A, Michieli M, Ribera JM et al (2009) Autologous stem cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 27:2192–2198CrossRefPubMedGoogle Scholar
  73. 73.
    Re A, Cattaneo C, Skert C, Balsalobre P, Michieli M et al (2013) Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica 98:1762–1768PubMedCentralCrossRefPubMedGoogle Scholar
  74. 74.
    Diez-Martin JL, Balsalobre P, Re A, Michieli M, Ribera JM et al (2009) Comparable survival between HIV+and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 113:6011–6014CrossRefPubMedGoogle Scholar
  75. 75.
    Hensel M, Goetzenich A, Lutz T, Stoehr A, Moll A et al (2011) HIV and cancer in Germany. Dtsch Arztebl Int 108:117–122PubMedCentralPubMedGoogle Scholar
  76. 76.
    Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J (2006) Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst 98:1088–1091CrossRefPubMedGoogle Scholar
  77. 77.
    Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A et al (2001) Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 15:2119–2127CrossRefPubMedGoogle Scholar
  78. 78.
    Kasamon YL, Ambinder RF (2005) AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am 19:665–687CrossRefPubMedGoogle Scholar
  79. 79.
    Uldrick TS, Pipkin S, Scheer S, Hesssol NA. (2013) Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. AIDS Sep 26 [Epub ahead of print]Google Scholar
  80. 80.
    Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE et al (2004) Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 100:2627–2636CrossRefPubMedGoogle Scholar
  81. 81.
    Nagai H, Odawara T, Ajisawa A, Tanuma J, Hagiwara S et al (2010) Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol 84:499–505CrossRefPubMedGoogle Scholar
  82. 82.
    Aboulafia DM, Puswella AL (2007) Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS 21:900–097CrossRefPubMedGoogle Scholar
  83. 83.
    Travi G, Ferreri AJ, Cinque P, Gerevini S, Ponzoni M (2012) Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. J Clin Oncol 30:e119–121CrossRefPubMedGoogle Scholar
  84. 84.
    Jacomet C, Girard PM, Librette MG, Farese VL, Monfort L, Rozenbaum W (1997) Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS 11:1725–1730CrossRefPubMedGoogle Scholar
  85. 85.
    Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I et al (2003) Incidence of non-AIDS-defining cancer before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21:3447–3453CrossRefPubMedGoogle Scholar
  86. 86.
    Powles T, Robinson D, Stebbing J, Shamash J, Nelson M et al (2009) Highly active antiretroviral therapy and the incidence of non–AIDS-defining cancers in people with HIV infection. J Clin Oncol 27:884–890CrossRefPubMedGoogle Scholar
  87. 87.
    Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F et al (2010) Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 103:416–422PubMedCentralCrossRefPubMedGoogle Scholar
  88. 88.
    Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA (2006) Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108:3786–3791PubMedCentralCrossRefPubMedGoogle Scholar
  89. 89.
    Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V et al (2011) HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood 118:44–49PubMedCentralCrossRefPubMedGoogle Scholar
  90. 90.
    Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M et al (2011) HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood 117:6100–6108CrossRefPubMedGoogle Scholar
  91. 91.
    Gérard L, Galicier L, Boulanger E, Quint L, Lebrette MG et al (2003) Improved survival in HIV-related Hodgkin’s lymphoma since the introduction of highly active antiretroviral therapy. AIDS 17:81–87CrossRefPubMedGoogle Scholar
  92. 92.
    Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ et al (2004) Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol 124:455–462CrossRefGoogle Scholar
  93. 93.
    Hentrich M, Maretta L, Chow KU, Bogner JR, Schürmann D et al (2006) Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin’s disease: results of a multicenter study. Ann Oncol 17:914–919CrossRefPubMedGoogle Scholar
  94. 94.
    Xicoy B, Ribera J-M, Miralles P, Berenguer J, Rubio R et al (2007) Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica 92:191–198CrossRefPubMedGoogle Scholar
  95. 95.
    Montoto S, Shaw K, Okosun J, Gandhi S, Fields P et al (2012) HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 30:4111–4116CrossRefPubMedGoogle Scholar
  96. 96.
    Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C et al (2002) Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 100:1984–1988CrossRefPubMedGoogle Scholar
  97. 97.
    Engert A, Plütschow A, Eich HT, Lohri A, Dörken B et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640–652CrossRefPubMedGoogle Scholar
  98. 98.
    Rancea M, Engert A, von Tresckow B, Halbsguth T, Behringer K, Skoetz N (2013) Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up. Dtsch Arztebl Int 110:177–83PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Marcus Hentrich
    • 1
  • Christian Hoffmann
    • 2
  • Franz Mosthaf
    • 3
  • Markus Müller
    • 4
  • Jan Siehl
    • 5
  • Christoph Wyen
    • 6
  • Manfred Hensel
    • 7
  1. 1.Department of Hematology, Oncology and Palliative CareHarlaching Hospital, Academic Teaching Hospital of the University of MunichMunichGermany
  2. 2.IPM Study CenterHamburg and University of Schleswig HolsteinKielGermany
  3. 3.Hematology, Oncology and Infectious Diseases PracticeKarlsruheGermany
  4. 4.Department of Infectious DiseasesVivantes Auguste-Viktoria-HospitalBerlinGermany
  5. 5.Hematology, Oncology and Infectious Diseases PracticeBerlinGermany
  6. 6.First Department of Internal MedicineUniversity of CologneCologneGermany
  7. 7.Hematology, Oncology and Infectious Diseases PracticeMannheimGermany

Personalised recommendations